AGEs, RAGE, and diabetic retinopathy

Current Diabetes Reports

Volumn 11, Issue 4, 2011, Pages 244-252

  Zong, Hongliang ^a   Ward, Micheal ^a   Stitt, Alan W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Advanced glycation end products (AGEs); Diabetic retinopathy; Inflammation; RAGE blockade; Receptor for AGEs (RAGE)

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOGENESIS INHIBITOR; ASCORBIC ACID; BEVACIZUMAB; ERYTHROPOIETIN; ETODOLAC; K 163; KIOM 79; MINODRONIC ACID; OLMESARTAN; PEGAPTANIB; PF 4494700; PYRIDOXAMINE; RANIBIZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LOW DRUG DOSE; MICROGLIA; MUELLER CELL; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; RETINA CELL; RETINA MACULA EDEMA; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; DIABETIC RETINOPATHY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 80051599575     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-011-0198-7     Document Type: Article

References (67)

1. AW Stitt 2010 AGEs and diabetic retinopathy Invest Ophthalmol Vis Sci 51 4867 74 20876889 10.1167/iovs.10-5881
2. X Zhang JB Saaddine CF Chou, et al. 2010 Prevalence of diabetic retinopathy in the United States, 2005-2008 JAMA 304 649 56 20699456 10.1001/jama.2010.1111 1:CAS:528:DC%2BC3cXhtVelsbvE
3. Q Mohamed MC Gillies TY Wong 2007 Management of diabetic retinopathy: a systematic review JAMA 298 902 16 17712074 10.1001/jama.298.8.902 1:CAS:528:DC%2BD2sXpsFCrtLg%3D (Pubitemid 47311296)
4. B Mannervik 2008 Molecular enzymology of the glyoxalase system Drug Metabol Drug Interact 23 13 27 18533362 10.1515/DMDI.2008.23.1-2.13 1:CAS:528:DC%2BD1cXmtFams7s%3D (Pubitemid 351669563)
5. T Goldberg W Cai M Peppa, et al. 2004 Advanced glycoxidation end products in commonly consumed foods J Am Diet Assoc 104 1287 91 15281050 10.1016/j.jada.2004.05.214 1:CAS:528:DC%2BD2cXntV2ktL4%3D (Pubitemid 39036519)
6. PC Chao CN Huang CC Hsu MC Yin YR Guo 2010 Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1alpha and MCP-1 levels in type 2 diabetic patients Eur J Nutr 49 429 34 20229096 10.1007/s00394-010-0101-3 1:CAS:528:DC%2BC3cXht1Slt7%2FL
7. W Cai QD Gao L Zhu M Peppa C He H Vlassara 2002 Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction Mol Med 8 337 46 12393931 1:CAS:528:DC%2BD38XnvFyjt7k%3D (Pubitemid 35346213)
8. J Uribarri W Cai O Sandu M Peppa T Goldberg H Vlassara 2005 Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects Ann NY Acad Sci 1043 461 6 16037267 10.1196/annals.1333.052 1:CAS:528:DC%2BD2MXpvVKqt7k%3D (Pubitemid 41123934)
9. SY Goh ME Cooper 2008 Clinical review: the role of advanced glycation end products in progression and complications of diabetes J Clin Endocrinol Metab 93 1143 52 18182449 10.1210/jc.2007-1817 1:CAS:528:DC%2BD1cXks1ahtb0%3D (Pubitemid 351519698)
10. H Vlassara 2001 The AGE-receptor in the pathogenesis of diabetic complications Diab Metab Res Rev 17 436 43 10.1002/dmrr.233 1:CAS:528: DC%2BD38XnsFSktg%3D%3D (Pubitemid 34030746)
11. AM Schmidt M Vianna M Gerlach, et al. 1992 Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface J Biol Chem 267 14987 97 1321822 1:CAS:528:DyaK38Xls1Kisbk%3D
12. • Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 2009, 116:621-637. This study has had an important impact because it reviewed the role of RAGE in the pathogenesis of vascular disease and contains all the seminal research in this field.
13. M Osawa Y Yamamoto S Munesue, et al. 2007 De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts Biochim Biophys Acta 1770 1468 74 17714874 1:CAS:528:DC%2BD2sXhtVCitrnP (Pubitemid 47384994)
14. E Leclerc G Fritz M Weibel CW Heizmann A Galichet 2007 S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains J Biol Chem 282 31317 31 17726019 10.1074/jbc.M703951200 1:CAS:528:DC%2BD2sXhtFykurjM (Pubitemid 350044892)
15. MA Hofmann S Drury C Fu, et al. 1999 RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides Cell 97 889 901 10399917 10.1016/S0092-8674(00)80801-6 1:CAS:528:DyaK1MXktlCltrc%3D (Pubitemid 29375048)
16. BI Hudson AM Carter E Harja, et al. 2008 Identification, classification, and expression of RAGE gene splice variants FASEB J 22 1572 80 18089847 10.1096/fj.07-9909com 1:CAS:528:DC%2BD1cXltlWksL8%3D (Pubitemid 351656797)
17. C Falcone E Emanuele A D'Angelo, et al. 2005 Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arterioscler Thromb Vasc Biol 25 1032 7 15731496 10.1161/01.ATV.0000160342.20342.00 1:CAS:528:DC%2BD2MXjsVCjt7s%3D (Pubitemid 40627851)
18. H Zong A Madden M Ward MH Mooney CT Elliott AW Stitt 2010 Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction J Biol Chem 285 23137 46 20504772 10.1074/jbc.M110.133827 1:CAS:528:DC%2BC3cXovFelsrw%3D
19. SF Yan R Ramasamy LG Bucciarelli, et al. 2004 RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res 1 10 20 16305050 10.3132/dvdr.2004.001
20. BI Hudson AZ Kalea M Del Mar Arriero, et al. 2008 Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42 J Biol Chem 283 34457 68 18922799 10.1074/jbc.M801465200 1:CAS:528:DC%2BD1cXhsVelu7jK
21. Y Xu F Toure W Qu, et al. 2010 Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages J Biol Chem 285 23233 40 20507991 10.1074/jbc.M110.117457 1:CAS:528:DC%2BC3cXovFelsLw%3D
22. K Takuma F Fang W Zhang, et al. 2009 RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction Proc Natl Acad Sci USA 106 20021 6 19901339 1:CAS:528:DC%2BD1MXhsFGjtLvO
23. HJ Huttunen C Fages H Rauvala 1999 Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways J Biol Chem 274 19919 24 10391939 10.1074/jbc.274.28.19919 1:CAS:528:DyaK1MXksFKmu74%3D (Pubitemid 29327777)
24. Bianchi R, Kastrisianaki E, Giambanco I, Donato R. S100B protein stimulates microglia migration via RAGE-dependent upregulation of chemokine expression and release. J Biol Chem 2011
25. DS Fosmark R Bragadottir I Stene-Johansen, et al. 2007 Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study Acta Ophthalmol Scand 85 618 22 17488318 10.1111/j.1600-0420.2007.00913.x 1:CAS:528:DC%2BD2sXhtFanurvF (Pubitemid 47316760)
26. T Murata R Nagai T Ishibashi H Inomuta K Ikeda S Horiuchi 1997 The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas Diabetologia 40 764 9 9243096 10.1007/s001250050747 1:CAS:528:DyaK2sXksFemsr4%3D (Pubitemid 27306953)
27. AW Stitt T Bhaduri CB McMullen TA Gardiner DB Archer 2000 Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats Mol Cell Biol Res Commun 3 380 8 11032761 10.1006/mcbr.2000.0243 1:CAS:528:DC%2BD3cXotlGiurg%3D
28. AW Stitt TM Curtis 2005 Advanced glycation and retinal pathology during diabetes Pharmacol Rep 57 Suppl 156 68 16415497
29. GR Barile SI Pachydaki SR Tari, et al. 2005 The RAGE axis in early diabetic retinopathy Invest Ophthalmol Vis Sci 46 2916 24 16043866 10.1167/iovs.04-1409 (Pubitemid 43086714)
30. •• Zong H, Ward M, Madden A, et al. Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010, 53:2656-2666. This paper demonstrated that RAGE interaction with its ligands plays an important role in retinal glial dysfunction during diabetic retinopathy. RAGE and its ligand S100B were induced by hyperglycemia in Müller glia, in vitro and in vivo. The early induction of S100B/RAGE expression by hyperglycemia in Muller glia results in the elevated levels of proinflammatory cytokines including VEGF and MCP-1, which are key mediators for diabetic retinopathy. This response can be attenuated by sRAGE or RAGE small interfering RNA, implicating the critical role of RAGE in the initiation of diabetic retinopathy.
31. • Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59:249-255. This paper is important because it evaluated the induction of RAGE and its ligands, S100A8, S100A12, and HMGB1, in human aortic endothelial cells and indicated modulation by ROS. This suggests that ROS cannot only be induced as the end point of RAGE activation, but also act as a positive feedback of RAGE-mediated proinflammatory signaling.
32. EL Fletcher JA Phipps MM Ward T Puthussery JL Wilkinson-Berka 2007 Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy Curr Pharm Des 13 2699 712 17897014 10.2174/138161207781662920 1:CAS:528:DC%2BD2sXhtV2gtrfE (Pubitemid 47423662)
33. C Hirata K Nakano N Nakamura, et al. 1997 Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells Biochem Biophys Res Commun 236 712 15 9245719 10.1006/bbrc.1997.7036 1:CAS:528:DyaK2sXltVKks7g%3D (Pubitemid 27384695)
34. E Lieth AJ Barber B Xu, et al. 1998 Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group Diabetes 47 815 20 9588455 10.2337/diabetes.47.5.815 1:CAS:528:DyaK1cXjs1Sgsbg%3D (Pubitemid 28201813)
35. TM Curtis R Hamilton PH Yong, et al. 2011 Muller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products Diabetologia 54 690 8 21116609 10.1007/s00125-010-1971-x 1:CAS:528:DC%2BC3MXhsFKjt7s%3D
36. R Donato 2001 S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles Int J Biochem Cell Biol 33 637 68 11390274 10.1016/S1357-2725(01)00046-2 1:CAS:528:DC%2BD3MXktVKltro%3D (Pubitemid 32520962)
37. CD Mills K Kincaid JM Alt MJ Heilman AM Hill 2000 M-1/M-2 macrophages and the Th1/Th2 paradigm J Immunol 164 6166 73 10843666 1:CAS:528: DC%2BD3cXktFWlsbw%3D (Pubitemid 30408793)
38. CG Schalkwijk N Ligtvoet H Twaalfhoven, et al. 1999 Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries Diabetes 48 2446 53 10580435 10.2337/diabetes.48.12.2446 1:CAS:528: DyaK1MXnslOqurY%3D (Pubitemid 30395438)
39. TC Moore JE Moore Y Kaji, et al. 2003 The role of advanced glycation end products in retinal microvascular leukostasis Invest Ophthalmol Vis Sci 44 4457 64 14507893 10.1167/iovs.02-1063 (Pubitemid 37186283)
40. BH Chen DY Jiang LS Tang 2006 Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes Life Sci 79 1040 8 16674981 10.1016/j.lfs.2006.03.020 1:CAS:528:DC%2BD28XntlWqtrY%3D (Pubitemid 44067065)
41. WS Foulds 1990 The choroidal circulation and retinal metabolism-an overview Eye (Lond) 4 Pt 2 243 8 (Pubitemid 20307080)
42. M Lu M Kuroki S Amano, et al. 1998 Advanced glycation end products increase retinal vascular endothelial growth factor expression J Clin Invest 101 1219 24 9502762 10.1172/JCI1277 1:CAS:528:DyaK1cXitVWjt74%3D (Pubitemid 28145237)
43. S Yamagishi K Nakamura T Matsui, et al. 2006 Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J Biol Chem 281 20213 20 16707486 10.1074/jbc.M602110200 1:CAS:528:DC%2BD28XmvFeqt70%3D (Pubitemid 44065796)
44. S Sheikpranbabu R Haribalaganesh KJ Lee S Gurunathan 2010 Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability Biochimie 92 1040 51 20470857 10.1016/j.biochi. 2010.05.004 1:CAS:528:DC%2BC3cXovFyltbw%3D
45. M Nitti AL Furfaro N Traverso, et al. 2007 PKC delta and NADPH oxidase in AGE-induced neuronal death Neurosci Lett 416 261 5 17317001 10.1016/j.neulet.2007.02.013 1:CAS:528:DC%2BD2sXjslSqtLc%3D (Pubitemid 46483861)
46. Y Wang F Vom Hagen F Pfister, et al. 2008 Receptor for advanced glycation end product expression in experimental diabetic retinopathy Ann NY Acad Sci 1126 42 5 18448794 10.1196/annals.1433.063 1:CAS:528:DC%2BD1cXmtFygtb0%3D (Pubitemid 351589325)
47. HP Hammes S Martin K Federlin K Geisen M Brownlee 1991 Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy Proc Natl Acad Sci USA 88 11555 8 1763069 10.1073/pnas.88.24.11555 1:CAS:528:DyaK38XpvFWntA%3D%3D (Pubitemid 21916080)
48. P Canning JV Glenn DK Hsu FT Liu TA Gardiner AW Stitt 2007 Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes Exp Diabetes Res 2007 51837 17641742
49. S Yatoh M Mizutani T Yokoo, et al. 2006 Antioxidants and an inhibitor of advanced glycation ameliorate death of retinal microvascular cells in diabetic retinopathy Diabetes Metab Res Rev 22 38 45 15892182 10.1002/dmrr.562 1:CAS:528:DC%2BD28Xhs1Kku7c%3D (Pubitemid 43154460)
50. A Bhatwadekar JV Glenn JL Figarola, et al. 2008 A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats Br J Ophthalmol 92 545 7 18211931 10.1136/bjo.2007.127910 1:STN:280: DC%2BD1c3hsVagsA%3D%3D (Pubitemid 351497988)
51. Y Kaji T Usui S Ishida, et al. 2007 Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products Invest Ophthalmol Vis Sci 48 858 65 17251488 10.1167/iovs.06-0495 (Pubitemid 351260723)
52. Y Chen EM Akirav W Chen, et al. 2008 RAGE ligation affects T cell activation and controls T cell differentiation J Immunol 181 4272 8 18768885 1:CAS:528:DC%2BD1cXhtVKntbjO
53. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease. Alzheimer Dis Assoc Disord 2010
54. K Yamamoto W Kitayama A Denda T Sasahira H Kuniyasu T Kirita 2006 Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac Pathobiology 73 317 24 17374970 10.1159/000099127 1:CAS:528:DC%2BD2sXjt1ygurc%3D (Pubitemid 46479286)
55. S Yamagishi T Matsui K Nakamura, et al. 2008 Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species Ophthalmic Res 40 10 15 18025836 10.1159/000111152 1:CAS:528:DC%2BD1cXit1KksQ%3D%3D (Pubitemid 350308297)
56. N Marx D Walcher N Ivanova, et al. 2004 Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products Diabetes 53 2662 8 15448098 10.2337/diabetes.53.10.2662 1:CAS:528:DC%2BD2cXotFymt7g%3D (Pubitemid 39299276)
57. S Yamagishi M Takeuchi 2004 Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation Drugs Exp Clin Res 30 169 75 15553663 1:CAS:528:DC%2BD2cXhtVKisbjJ (Pubitemid 39487685)
58. A Praidou S Androudi P Brazitikos G Karakiulakis E Papakonstantinou S Dimitrakos 2010 Angiogenic growth factors and their inhibitors in diabetic retinopathy Curr Diabetes Rev 6 304 12 20594164 10.2174/157339910793360815 1:CAS:528:DC%2BC3cXht1CjsL%2FF
59. W Abdallah AA Fawzi 2009 Anti-VEGF therapy in proliferative diabetic retinopathy Int Ophthalmol Clin 49 95 107 19349790 10.1097/IIO.0b013e31819fd84a
60. J Gaudreault D Fei J Rusit P Suboc V Shiu 2005 Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration Invest Ophthalmol Vis Sci 46 726 33 15671306 10.1167/iovs.04-0601 (Pubitemid 40270359)
61. N Ferrara KJ Hillan HP Gerber W Novotny 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 391 400 15136787 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D (Pubitemid 38618122)
62. JF Arevalo M Maia HW Flynn Jr, et al. 2008 Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy Br J Ophthalmol 92 213 16 17965108 10.1136/bjo.2007.127142 1:STN:280:DC%2BD1c%2FmvFWhsA%3D%3D (Pubitemid 351224097)
63. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011.
64. OS Kim J Kim CS Kim NH Kim JS Kim 2010 KIOM-79 prevents methyglyoxal-induced retinal pericyte apoptosis in vitro and in vivo J Ethnopharmacol 129 285 92 20362656 10.1016/j.jep.2010.03.027
65. Q Wang F Pfister A Dorn-Beineke, et al. 2010 Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina Diabetologia 53 1227 38 20339831 10.1007/s00125-010-1727-7 1:CAS:528:DC%2BC3cXlt1Omsrg%3D
66. S Yamagishi K Nakamura T Matsui M Takeuchi 2006 Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy Med Hypotheses 66 273 5 16216433 10.1016/j.mehy.2005. 08.042 1:CAS:528:DC%2BD2MXhtlSjsbnF (Pubitemid 41773900)
67. RA Kowluru M Kanwar PS Chan JP Zhang 2008 Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients Arch Ophthalmol 126 1266 72 18779489 10.1001/archopht.126.9.1266